Close
RNS Number : 6882O
e-Therapeutics plc
22 August 2017
 

E-THERAPEUTICS PLC

 

("e-therapeutics" or the "Company")

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS

DISCHARGING MANAGERIAL RESPONSIBILITIES

 

                                                                                     

Oxford, UK, 22 August 2017 - e-therapeutics plc (AIM: ETX), the computer-based drug discovery platform company, announces that it has received notifications from two of its directors that they have purchased, in aggregate, 520,000 shares in the Company at a price of 10.6 pence per share. The purchases took place today.

The number of ordinary shares purchased by each director is set out below:          

Director

Number of shares purchased

Iain Ross

250,000

Ray Barlow

270,000

Mr Ross purchased the shares through his self-invested personal pension (SIPP) and, following these trades, the beneficial interests of those directors in ordinary shares of ETX are as follows:

Director

Number of shares held

Percentage of issued share capital

Iain Ross

1,250,000

0.47%

Ray Barlow

1,100,000

0.41%

 

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further details:

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Iain Ross

2

Reason for the notification

a)

Position/status 

Non-Executive Chairman

b)

Initial notification/ Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

e-therapeutics plc 

b)

LEI

21380049RHSSJXWKYT18

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code 

Ordinary shares of 0.1 pence

 

ISIN:   GB00B2823H99

b)

Nature of the transaction

Purchase of shares through self-invested personal pension (SIPP)

c)

Price(s) and volume(s)

250,000 ordinary shares at a price of 10.6 pence per share

d)

Aggregated information

- Aggregated volume

- Price

 

N/A

e)

Date of the transaction

22 August 2017 

f)

Place of the transaction

London Stock Exchange, AIM (XLON)

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Ray Barlow

2

Reason for the notification

a)

Position/status 

Chief Executive Officer

b)

Initial notification/ Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

e-therapeutics plc 

b)

LEI

21380049RHSSJXWKYT18

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code 

Ordinary shares of 0.1 pence

 

ISIN:   GB00B2823H99

b)

Nature of the transaction

Purchase of shares 

c)

Price(s) and volume(s)

270,000 ordinary shares at a price of 10.6 pence per share

d)

Aggregated information

- Aggregated volume

- Price

 

N/A

e)

Date of the transaction

22 August 2017 

f)

Place of the transaction

London Stock Exchange, AIM (XLON)

 

 

 

 

For further information, please contact:

 

e-therapeutics plc

Ray Barlow, Chief Executive Officer

Steve Medlicott, Finance Director

 

Tel: +44 (0) 1993 883 125

www.etherapeutics.co.uk 

 

Numis Securities Limited

Michael Meade/Freddie Barnfield
(Corporate Finance)

James Black (Corporate Broking)

 

Tel: +44 (0) 207 260 1000

www.numis.com

 

Instinctif Partners

Melanie Toyne Sewell/Alex Shaw

Tel: +44 (0) 207 457 2020

Email: e-therapeutics@instinctif.com

 

 

About e-therapeutics plc

We are an Oxford-based company with a unique and powerful computer-based drug discovery platform and a specialised approach to network biology.  

Our novel methodology and our Discovery Engine allow us to discover new and better drugs in a more efficient and effective way.

e-therapeutics is headquartered in Oxford. For more information about the Company please visit www.etherapeutics.co.uk.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFLVTFIFFID